Experts still see some hope for Avastin in adjuvant colon cancer
This article was originally published in Scrip
Roche's (Genentech) Avastin (bevacizumab) may have failed in its first Phase III trial in adjuvant cancer – one of the most closely watched oncology drug trials of the year – because the duration of treatment with the VEGF-targeted therapy was not long enough, the trial's investigators told a plenary session at this week's ASCO meeting in Orlando. They revealed data showing that Avastin showed a benefit in stopping colon cancer from recurring over the year that it was administered, but this benefit diminished in subsequent years.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.